NetworkNewsBreaks – VistaGen Therapeutics, Inc. (NASDAQ: VTGN) Obtains Fast Track Designation on AV-101 to Treat Neuropathic Pain
VistaGen Therapeutics (NASDAQ: VTGN) recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for development of AV-101 as a non-opioid, non-sedating treatment for neuropathic pain, marking the second Fast Track designation granted to the company since December 2017. This designation facilitates the development, and possibly accelerate the review, of drugs that fill an unmet medical need to treat serious or life-threatening conditions. “Every day in the U.S., more than 115 people die from overdosing on opioids. We have evaluated AV-101 in multiple models of serious CNS conditions, including those that cause patients to suffer…